{"id":4293,"date":"2001-04-17T21:10:47","date_gmt":"2001-04-17T20:10:47","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4293"},"modified":"2014-06-12T14:05:55","modified_gmt":"2014-06-12T14:05:55","slug":"european-activists-demand-greater-access-to-t-20","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4293","title":{"rendered":"European activists demand greater access to T-20"},"content":{"rendered":"<p><strong>AIDS activists demanded on Tuesday that two companies improve access to an investigational antiretroviral drug, T-20, which has shown activity in HIV-infected patients who have failed conventional therapy. T-20 is the first of a new class of antiretroviral drugs called fusion inhibitors, which block HIV cell entry.<\/strong><\/p>\n<p>The European AIDS Treatment Group said a plan by Swiss-based Roche and its US partner Trimeris to offer T-20 to just 450 people under an expanded access programme was &#8220;catastrophically&#8221; inadequate. Another 550 to 600 patients will receive the drug in clinical trials.<\/p>\n<p>Roche spokeswoman Maria Vigneau said Roche and Trimeris were unable to make more of the drug available because of the manufacturing constraints. &#8220;It&#8217;s a very complex drug and requires a novel peptide manufacturing process which has never been performed before at the scale required,&#8221; she said.<\/p>\n<p>The drug is currently being made at a pilot plant in Boulder, Colorado, which will only be scaled up to full production in the middle of 2002. Although T-20 has a number of disadvantages, it must be given by injection twice daily and can cause inflammation at the injection site, it is active against resistant HIV strains.<\/p>\n<p>T-20 is now in late-stage, Phase III, trials and the companies hope the US Food and Drug Administration will approve the product for sale by late 2002.<\/p>\n<p>Both T-20 and a second-generation fusion inhibitor in development called T-1249 have already received fast-track status from the FDA. Data released in January showed that T-20 and T-1249 were both potent inhibitors of HIV replication and were well tolerated.<\/p>\n<p>Source: Reuters Health<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AIDS activists demanded on Tuesday that two companies improve access to an investigational antiretroviral drug, T-20, which has shown activity in HIV-infected patients who have failed conventional therapy. T-20 is the first of a new class of antiretroviral drugs called &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-4293","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4293"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4293\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}